20/20 BioLabs, a biotechnology company, announced its financial results for the first quarter of 2026, ending March 31, 2026. The company reported total revenue of $12.5 million, primarily from its laboratory services and research partnerships. This represents a 15% increase compared to the same period in 2025.
Net loss for the quarter was $3.2 million, or $0.08 per share, compared to a net loss of $2.8 million in Q1 2025. The increase in net loss was attributed to higher research and development expenses, which rose to $4.1 million from $3.5 million year-over-year, as the company expanded its drug discovery programs.
Operationally, 20/20 BioLabs continued to advance its pipeline of therapeutic candidates. The company highlighted progress in its oncology program, with preclinical data expected in the second half of 2026. Cash and cash equivalents stood at $45.6 million as of March 31, 2026, providing sufficient runway into 2028.
Management expressed confidence in the company's strategic direction, focusing on leveraging its proprietary technology platform for targeted therapies. The company did not provide specific revenue guidance for the full year 2026 but reiterated its commitment to operational efficiency and value creation for shareholders.
